Efficacy of Neoadjuvant Denosumab on Tumor Recurrence, Ossification, and Surgical Outcomes in Patients With Grade III Giant Cell Tumor of Bone: A Prospective, Non‐Randomized Comparative Interventional Study
Mehdi Karimi, Samira Pirzad, Kimia Habibi, Masoud Mirkazemi. Efficacy of Neoadjuvant Denosumab on Tumor Recurrence, Ossification, and Surgical Outcomes in Patients With Grade III Giant Cell Tumor of Bone: A Prospective, Non‐Randomized Comparative Interventional Study. // Asia-Pacific Journal of Clinical Oncology. – 2026. – DOI: 10.1111/ajco.70153. – URL: https://onlinelibrary.wiley.com/doi/10.1111/ajco.70153?af=R
Mehdi Karimi, Samira Pirzad, Kimia Habibi, & Masoud Mirkazemi (2026). Efficacy of Neoadjuvant Denosumab on Tumor Recurrence, Ossification, and Surgical Outcomes in Patients With Grade III Giant Cell Tumor of Bone: A Prospective, Non‐Randomized Comparative Interventional Study. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70153
Mehdi Karimi, et al. “Efficacy of Neoadjuvant Denosumab on Tumor Recurrence, Ossification, and Surgical Outcomes in Patients With Grade III Giant Cell Tumor of Bone: A Prospective, Non‐Randomized Comparative Interventional Study.” Asia-Pacific Journal of Clinical Oncology, 2026. doi:10.1111/ajco.70153.
@article{Karimi2026,
title = {Efficacy of Neoadjuvant Denosumab on Tumor Recurrence, Ossification, and Surgical Outcomes in Patients With Grade III Giant Cell Tumor of Bone: A Prospective, Non‐Randomized Comparative Interventional Study},
author = {Karimi, Mehdi and Pirzad, Samira and Habibi, Kimia and Mirkazemi, Masoud},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
doi = {10.1111/ajco.70153},
url = {https://onlinelibrary.wiley.com/doi/10.1111/ajco.70153?af=R}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment